News | Cardiovascular Clinical Studies | October 20, 2023

JenaValve Announces ALIGN-AR Pivotal Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2023

The ALIGN-AR trial is a landmark prospective, single-arm investigation device exemption (IDE) study designed to assess the safety and efficacy of the Trilogy THV System

October 20, 2023 — JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) System, announced that data from the ALIGN-AR Pivotal Trial will be presented by Dr. Vinod Thourani (Piedmont Heart Institute, Atlanta, GA) during the Late-Breaking Clinical Trial sessions at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in San Francisco, CA. The presentation will take place on Tuesday, October 24th, at 12:06 PM Pacific Time. 

Prior to the data presentation, at 11:00 AM Pacific Time, a procedure using the CE Mark approved Trilogy THV System will be shown via broadcast from the University of Cologne. Additionally, a symposium focusing on the Trilogy THV System as a solution to address the unmet need in aortic regurgitation (AR) is scheduled for Thursday, October 26th at 2:15 PM Pacific Time. 

The ALIGN-AR trial is a landmark prospective, single-arm investigation device exemption (IDE) study designed to assess the safety and efficacy of the Trilogy THV System in high-risk patients with symptomatic, severe AR. Results from the study are intended to support a Premarket Approval submission to the U.S. Food and Drug Administration (FDA). If approved, the Trilogy THV System would become the first and only transcatheter aortic valve replacement (TAVR) system in the U.S. indicated for the treatment of symptomatic, severe AR. 

For additional information on the ALIGN-AR Trial or JenaValve, visit the JenaValve team at Booth #215 at TCT. 

For more information: www.jenavalve.com 

 

Find more TCT23 conference coverage here 

 

Related coverage: 

TCT23 Late-breakers: Full Schedule Announced 

TCT 2023 Leadership Anticipates 'Practice Changing' Findings Ahead of 35th Scientific Symposium 

CRF Announces TCT 2023 Late-breaking Clinical Trials 

MedTech Innovation Forum Leads Day One at TCT 2023 

Cardiovascular Research Foundation Announces Clinical Trials Center Executive Director 


Additional Content

News | TCT

Nov. 2, 2026 — At the Transcatheter Cardiovascular Therapeutics (TCT) annual conference in San Diego, Calif. Medtronic ...

Home November 04, 2026
Home
News | TCT

Nov. 1, 2026 — Heartflow, Inc. has announced new landmark randomized clinical data presented at Transcatheter ...

Home November 02, 2026
Home
News | TCT

Oct. 29, 2026 — Johnson & Johnson has announced 26 presentations featuring the clinical science of Impella heart pumps ...

Home October 30, 2026
Home
News | TCT

Aug. 26, 2026 – The Cardiovascular Research Foundation (CRF) announced the late-breaking clinical trials and science ...

Home August 31, 2026
Home
News | TCT

Oct. 23, 2025 — At TCT 2025, the Cardiovascular Research Foundation (CRF) announced the 2025 SET-10 (Scientific ...

Home October 31, 2025
Home
Subscribe Now